ProPhase Labs, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Net Loss Per Share

Net Loss Per Share

12 Months Ended

Dec. 31, 2024

Basic loss per share excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted loss per share also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):


	For the years ended
	December 31, 2024		December 31, 2023
Loss from continuing operations after income taxes	$	(49,525)	$	(16,380)
Loss from discontinued operations, net of tax	(3,839)		(402)
Net loss	$	(53,364)	$	(16,782)
Weighted average common shares outstanding:
Basic	20,463		17,207
Diluted	20,463		17,207
Net loss per share:
Loss from continuing operations, basic and diluted	$	(2.42)	$	(0.95)
Loss from discontinued operations, basic and diluted	$	(0.19)	$	(0.02)
Net loss per share, basic and diluted	$	(2.61)	$	(0.98)

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):


	For the years ended
Anti-dilutive securities	December 31, 2024	December 31, 2023
Common stock purchase warrants	616	831
Stock Options	3,881	2,951
Anti-dilutive securities	4,497	3,782